CytomX Therapeutics, Inc. (CTMX): Price and Financial Metrics


CytomX Therapeutics, Inc. (CTMX): $1.84

0.01 (+0.55%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CTMX POWR Grades


  • Value is the dimension where CTMX ranks best; there it ranks ahead of 66.95% of US stocks.
  • CTMX's strongest trending metric is Stability; it's been moving down over the last 179 days.
  • CTMX ranks lowest in Momentum; there it ranks in the 4th percentile.

CTMX Stock Summary

  • Of note is the ratio of CytomX Therapeutics Inc's sales and general administrative expense to its total operating expenses; merely 11.01% of US stocks have a lower such ratio.
  • As for revenue growth, note that CTMX's revenue has grown -30.68% over the past 12 months; that beats the revenue growth of only 5.43% of US companies in our set.
  • CytomX Therapeutics Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -59.55%, greater than the shareholder yield of only 7.39% of stocks in our set.
  • Stocks that are quantitatively similar to CTMX, based on their financial statements, market capitalization, and price volatility, are LPTX, SQZ, TMDI, EIGR, and GLYC.
  • Visit CTMX's SEC page to see the company's official filings. To visit the company's web site, go to www.cytomx.com.

CTMX Valuation Summary

  • In comparison to the median Healthcare stock, CTMX's price/earnings ratio is 114.25% lower, now standing at -5.2.
  • CTMX's price/sales ratio has moved down 56.3 over the prior 72 months.
  • Over the past 72 months, CTMX's EV/EBIT ratio has gone up 14.3.

Below are key valuation metrics over time for CTMX.

Stock Date P/S P/B P/E EV/EBIT
CTMX 2021-08-31 5.0 2.5 -5.2 -1.5
CTMX 2021-08-30 5.0 2.5 -5.1 -1.5
CTMX 2021-08-27 5.1 2.6 -5.3 -1.6
CTMX 2021-08-26 5.0 2.5 -5.1 -1.4
CTMX 2021-08-25 4.9 2.5 -5.1 -1.4
CTMX 2021-08-24 4.9 2.5 -5.1 -1.4

CTMX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CTMX has a Quality Grade of D, ranking ahead of 22.16% of graded US stocks.
  • CTMX's asset turnover comes in at 0.169 -- ranking 210th of 682 Pharmaceutical Products stocks.
  • JNJ, LEXX, and ORGS are the stocks whose asset turnover ratios are most correlated with CTMX.

The table below shows CTMX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.169 1 -0.872
2021-03-31 0.170 1 -0.944
2020-12-31 0.255 1 -0.424
2020-09-30 0.237 1 -0.610
2020-06-30 0.219 1 -0.636
2020-03-31 0.200 1 -0.554

CTMX Price Target

For more insight on analysts targets of CTMX, see our CTMX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $13.00 Average Broker Recommendation 1.5 (Moderate Buy)

CTMX Stock Price Chart Interactive Chart >

Price chart for CTMX

CTMX Price/Volume Stats

Current price $1.84 52-week high $7.53
Prev. close $1.83 52-week low $1.51
Day low $1.83 Volume 471,400
Day high $1.91 Avg. volume 1,000,252
50-day MA $1.75 Dividend yield N/A
200-day MA $3.96 Market Cap 120.33M

CytomX Therapeutics, Inc. (CTMX) Company Bio


CytomX Therapeutics develops a novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology. The company was founded in 2008 and is based in San Francisco, California.


CTMX Latest News Stream


Event/Time News Detail
Loading, please wait...

CTMX Latest Social Stream


Loading social stream, please wait...

View Full CTMX Social Stream

Latest CTMX News From Around the Web

Below are the latest news stories about CytomX Therapeutics Inc that investors may wish to consider to help them evaluate CTMX as an investment opportunity.

CytomX Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022

SOUTH SAN FRANCISCO, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it will report fourth quarter and full year 2021 financial results on Tuesday, March 1, 2022, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results and provide a corporate update. Participa

Yahoo | February 22, 2022

CytomX Therapeutics Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that on February 16, 2022, the Company granted nine new employees options to purchase a total of 189,400 shares of the Company’s common stock at an exercise price per share equal to $4.08, which was the closing trading price on February 15, 2022, the date of the grant. The stock options were granted pursua

Yahoo | February 16, 2022

CytomX Therapeutics Announces Promotion of Amy C. Peterson, M.D. to President and Chief Operating Officer

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced the promotion of Amy C. Peterson, M.D., to the position of president and chief operating officer, effective immediately. Dr. Peterson has served as the company’s executive vice president and chief development officer since October 2019 and will continue to report to Sean McCarthy, D. Phil., chief executive

Yahoo | February 7, 2022

Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | February 5, 2022

Myovant Sciences (MYOV) Reports Q3 Loss, Misses Revenue Estimates

Myovant Sciences (MYOV) delivered earnings and revenue surprises of -15.25% and 0.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | January 26, 2022

Read More 'CTMX' Stories Here

CTMX Price Returns

1-mo 3.37%
3-mo -34.98%
6-mo -55.34%
1-year N/A
3-year -83.62%
5-year -88.42%
YTD -57.51%
2021 -33.89%
2020 -21.18%
2019 -44.97%
2018 -28.47%
2017 92.08%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7494 seconds.